Applied DNA to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27
May 21 2020 - 11:11AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing that enables diagnostics, pre-clinical nucleic
acid-based therapeutic drug candidates, supply chain security,
anti-counterfeiting and anti-theft technology, announced that Dr.
James Hayward, president & CEO, will participate on a panel
titled ‘COVID-19 Testing and Monitoring’ at 12:15 p.m. ET on
Wednesday, May 27, 2020 as part of Maxim Group’s COVID-19 Virtual
Conference Series. The panel will be moderated by Jason McCarthy,
Ph.D., Maxim Group Senior Managing Director, Biotechnology.
A slide presentation to be used by Dr. Hayward during the panel
will be available to interested parties on the “Investors” section
of Applied DNA’s website at
https://adnas.com/molecular-based-security/investors/ at the start
of the panel.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
LinearDNA™ is a trademark of Applied DNA Sciences, Inc.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly-traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, the uncertainties inherent in
research and development, future clinical data and analysis,
including whether any of Applied DNA’s or its partners diagnostic
or therapeutic candidates will advance further in the preclinical
research or clinical trial process, including receiving clearance
from the U.S. Food and Drug Administration or equivalent foreign
regulatory agencies to conduct clinical trials and whether and
when, if at all, they will receive final approval from the U.S. FDA
or equivalent foreign regulatory agencies, the unknown outcome of
any applications to U.S. FDA or equivalent foreign regulatory
agencies, the unknown duration of this or any EUA approval,
disruptions in the supply of raw material and supplies, and various
other factors detailed from time to time in Applied DNA’s SEC
reports and filings, including our Annual Report on Form 10-K filed
on December 12, 2019 and our subsequent quarterly report on Form
10-Q filed on February 6, 2020, and other reports we file with the
SEC, which are available at www.sec.gov. Applied DNA undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200521005502/en/
Investors: Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.com
Web: www.adnas.com | twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2023 to Mar 2024